Pulmonary function and respiratory health after successful treatment of drug-resistant tuberculosis.
Adult
Bronchiectasis
/ epidemiology
Cohort Studies
Cross-Sectional Studies
Female
Forced Expiratory Volume
Georgia
/ epidemiology
Humans
Lung
/ physiopathology
Male
Middle Aged
Pulmonary Fibrosis
/ epidemiology
Radiography
Respiratory Function Tests
Retrospective Studies
Surveys and Questionnaires
Tuberculosis, Multidrug-Resistant
/ complications
Vital Capacity
Young Adult
Impairment
Lung health
Pulmonary function
St. George Respiratory Quality survey
Surgery
Tuberculosis
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
11
11
2018
revised:
21
02
2019
accepted:
24
02
2019
pubmed:
8
3
2019
medline:
17
7
2019
entrez:
8
3
2019
Statut:
ppublish
Résumé
Post-treatment morbidity among subjects with drug-resistant tuberculosis (DR-TB) is unclear. This was a cross-sectional study of patients from Tbilisi, Georgia with cavitary DR-TB and an outcome of cure. Participants had a chest X-ray (CXR), St. George Respiratory Quality (SGRQ) survey, and pulmonary function tests (PFTs) performed. Correlations between SGRQ and PFT results and factors associated with pulmonary impairment were examined. Among 58 subjects (median age 31 years), 40% used tobacco, 59% had prior TB, and 47% underwent adjunctive surgical resection. The median follow-up time was 41 months. Follow-up CXR revealed fibrosis in 30 subjects (52%) and bronchiectasis in seven (12%). The median forced expiratory volume (FEV A high proportion of DR-TB subjects had residual pulmonary impairment, particularly with recurrent TB and severe radiological disease. The association of surgical resection with improved lung function deserves further study. PFTs and SGRQ may both be useful to evaluate lung health.
Sections du résumé
BACKGROUND
BACKGROUND
Post-treatment morbidity among subjects with drug-resistant tuberculosis (DR-TB) is unclear.
METHODS
METHODS
This was a cross-sectional study of patients from Tbilisi, Georgia with cavitary DR-TB and an outcome of cure. Participants had a chest X-ray (CXR), St. George Respiratory Quality (SGRQ) survey, and pulmonary function tests (PFTs) performed. Correlations between SGRQ and PFT results and factors associated with pulmonary impairment were examined.
RESULTS
RESULTS
Among 58 subjects (median age 31 years), 40% used tobacco, 59% had prior TB, and 47% underwent adjunctive surgical resection. The median follow-up time was 41 months. Follow-up CXR revealed fibrosis in 30 subjects (52%) and bronchiectasis in seven (12%). The median forced expiratory volume (FEV
CONCLUSIONS
CONCLUSIONS
A high proportion of DR-TB subjects had residual pulmonary impairment, particularly with recurrent TB and severe radiological disease. The association of surgical resection with improved lung function deserves further study. PFTs and SGRQ may both be useful to evaluate lung health.
Identifiants
pubmed: 30844519
pii: S1201-9712(19)30103-1
doi: 10.1016/j.ijid.2019.02.039
pmc: PMC6528816
mid: NIHMS1528289
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
66-72Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR000455
Pays : United States
Organisme : AHRQ HHS
ID : K08 HS025240
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI122001
Pays : United States
Organisme : NHLBI NIH HHS
ID : L30 HL124529
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW007124
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000454
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI103044
Pays : United States
Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Eur Respir J. 2002 Mar;19(3):405-13
pubmed: 11936515
Int J Tuberc Lung Dis. 2004 Jun;8(6):767-71
pubmed: 15182148
Am Rev Respir Dis. 1992 Jun;145(6):1321-7
pubmed: 1595997
J Infect Dis. 2005 Oct 1;192(7):1201-9
pubmed: 16136463
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Thorax. 2006 Nov;61(11):935-9
pubmed: 17071833
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
pubmed: 1759018
Chest. 2007 Nov;132(5):1591-8
pubmed: 17890471
J Exp Med. 1918 Jan 1;27(1):129-42
pubmed: 19868191
J Exp Med. 1918 Jan 1;27(1):87-94
pubmed: 19868198
Lancet Infect Dis. 2012 Feb;12(2):157-66
pubmed: 22281142
Ann Thorac Surg. 2013 Jun;95(6):1892-8
pubmed: 23642435
Respiration. 2013;86(1):76-85
pubmed: 23652030
Int J Chron Obstruct Pulmon Dis. 2014 Jun 06;9:597-611
pubmed: 24944511
Am J Public Health. 2015 May;105(5):930-7
pubmed: 25790407
Int J Tuberc Lung Dis. 2015 Jun;19(6):676-8
pubmed: 25946358
Int J Tuberc Lung Dis. 2015 Jul;19(7):808-10
pubmed: 26056106
Int J Tuberc Lung Dis. 2016 Jan;20(1):43-8
pubmed: 26688527
Clin Infect Dis. 2016 Apr 1;62(7):887-895
pubmed: 26757804
Int J Tuberc Lung Dis. 2016 Aug;20(8):1010-4
pubmed: 27393532
Nat Med. 2016 Oct;22(10):1094-1100
pubmed: 27595324
Lancet Respir Med. 2017 Mar 15;:null
pubmed: 28344011
Lancet. 2017 May 13;389(10082):1931-1940
pubmed: 28513453
ERJ Open Res. 2017 Jul 12;3(3):null
pubmed: 28717643
Eur Respir J Suppl. 1993 Mar;16:5-40
pubmed: 8499054
Chest. 1998 Apr;113(4):933-43
pubmed: 9554628